DSM Reports Steady Growth, Seeks Deal in Pharmaceuticals

DSM has reported Ebitda for the second quarter of the year up 2% to €339 million ($482 million) on sales up 7% to €2.3 billion. Strong life sciences results were driven by robust growth in the group’s nutrition and materials businesses. The strong U.S. dollar negatively impacted the group overall, the company says.   The performance of the pharmaceuticals manufacturing business “remains below acceptable levels,” however, Sijbesma says. The pharma business recorded second quarter sales down 9% to €178 million. “We know...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers